Synthesis and Pharmacological Evaluation of 5-(4-Biphenyl)-3-methyl-4-phenyl-1,2,4-triazole Derivatives as a Novel Class of Selective Antagonists for the Human Vasopressin V1A Receptor-Reference-Cited by-同舟云学术

Synthesis and Pharmacological Evaluation of 5-(4-Biphenyl)-3-methyl-4-phenyl-1,2,4-triazole Derivatives as a Novel Class of Selective Antagonists for the Human Vasopressin V1A Receptor

Published:2002-05-11 Issue:12 Volume:45 Page:2589-2598
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Kakefuda Akio¹,Suzuki Takeshi¹,Tobe Takahiko¹,Tsukada Junko¹,Tahara Atsuo¹,Sakamoto Shuichi¹,Tsukamoto Shin-ichi¹

Affiliation:

1. Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co. Ltd., 21 Miyukigaoka, Tsukuba, Ibaraki 305-8585, Japan

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm010544r

Reference23 articles.

1. Molecular cloning of the receptor for human antidiuretic hormone

2. Molecular cloning, sequencing, and functional expression of a cDNA encoding the human V1a vasopressin receptor.

3. Signal transduction of V1-vascular vasopressin receptors

4. Hormonal Stimulation of Phosphatidylinositol Breakdown, with Particular Reference to the Hepatic Effects of Vasopressin

5. Characterization of human platelet vasopressin receptors.

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Pharmacological Update of Triazole Derivative: A Review;Current Topics in Medicinal Chemistry;2024-07-25

2. Isolation, synthesis and medicinal chemistry of biphenyl analogs – A review;Results in Chemistry;2023-12

3. On Features of Halocyclization of 4‐Allyl‐5‐substituted‐2,4‐dihydro‐3H‐1,2,4‐triazol‐3‐thiones and Synthesis of New Derivatives of 1,2,3‐Triazoles;ChemistrySelect;2022-05-18

4. Vasopressin and Its Analogues: From Natural Hormones to Multitasking Peptides;International Journal of Molecular Sciences;2022-03-12

5. Discovery of Balovaptan, a Vasopressin 1a Receptor Antagonist for the Treatment of Autism Spectrum Disorder;Journal of Medicinal Chemistry;2020-01-17